TD Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

TD Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-133,012	Closed	-$2.36M	–	1466
2018 Q3	$2.36M	Buy	133,012 +8,081	+6%	+$139K	﹤0.01%	949
2018 Q2	$1.72M	Sell	124,931 -11,000	-8%	-$131K	﹤0.01%	997
2018 Q1	$1.24M	Buy	+135,931	New	+$750K	﹤0.01%	1008
2014 Q1	–	Sell	-10,800	Closed	-$115K	–	1336
2013 Q4	$115K	Hold	10,800	–	–	﹤0.01%	1269
2013 Q3	$144K	Hold	10,800	–	–	﹤0.01%	1227
2013 Q2	$142K	Buy	+10,800	New	+$146K	﹤0.01%	1156

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

TD Asset Management's ECYT Position: Q4 2018 in Review

TD Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 133,012 shares — an estimated $2.36M sold.

TD Asset Management first reported a position in ECYT in Q2 2013 and held it in 6 quarters. The position peaked at $2.36M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

TD Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
TD Asset Management sold 133,012 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $2.36M.
TD Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
TD Asset Management's Endocyte, Inc. Common Stock position peaked at $2.36M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on TD Asset Management's 13F filing for Q4 2018, filed 1 Feb 2019.